دورية أكاديمية
IFN-γ-mediated control of SARS-CoV-2 infection through nitric oxide.
| العنوان: | IFN-γ-mediated control of SARS-CoV-2 infection through nitric oxide. |
|---|---|
| المؤلفون: | Silva BJA; Division of Dermatology, Department of Medicine, David Geffen School of Medicine at University of California (UCLA), Los Angeles, CA, United States., Krogstad PA; Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States.; Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA, United States., Teles RMB; Division of Dermatology, Department of Medicine, David Geffen School of Medicine at University of California (UCLA), Los Angeles, CA, United States., Andrade PR; Division of Dermatology, Department of Medicine, David Geffen School of Medicine at University of California (UCLA), Los Angeles, CA, United States., Rajfer J; Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States., Ferrini MG; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States.; Department of Health and Life Sciences, Charles R. Drew University of Medicine and Science, Los Angeles, CA, United States., Yang OO; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States.; Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States., Bloom BR; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, United States., Modlin RL; Division of Dermatology, Department of Medicine, David Geffen School of Medicine at University of California (UCLA), Los Angeles, CA, United States.; Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States. |
| المصدر: | Frontiers in immunology [Front Immunol] 2023 Dec 15; Vol. 14, pp. 1284148. Date of Electronic Publication: 2023 Dec 15 (Print Publication: 2023). |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | COVID-19*/immunology , Interferon-gamma*/immunology , Nitric Oxide*/immunology, Humans ; Angiotensin-Converting Enzyme 2 ; SARS-CoV-2/physiology ; Virus Replication |
| مستخلص: | Introduction: The COVID-19 pandemic has highlighted the need to identify mechanisms of antiviral host defense against SARS-CoV-2. One such mediator is interferon-g (IFN-γ), which, when administered to infected patients, is reported to result in viral clearance and resolution of pulmonary symptoms. IFN-γ treatment of a human lung epithelial cell line triggered an antiviral activity against SARS-CoV-2, yet the mechanism for this antiviral response was not identified. Methods: Given that IFN-γ has been shown to trigger antiviral activity via the generation of nitric oxide (NO), we investigated whether IFN-γ induction of antiviral activity against SARS-CoV-2 infection is dependent upon the generation of NO in human pulmonary epithelial cells. We treated the simian epithelial cell line Vero E6 and human pulmonary epithelial cell lines, including A549-ACE2, and Calu-3, with IFN-γ and observed the resulting induction of NO and its effects on SARS-CoV-2 replication. Pharmacological inhibition of inducible nitric oxide synthase (iNOS) was employed to assess the dependency on NO production. Additionally, the study examined the effect of interleukin-1b (IL-1β) on the IFN-g-induced NO production and its antiviral efficacy. Results: Treatment of Vero E6 cells with IFN-γ resulted in a dose-responsive induction of NO and an inhibitory effect on SARS-CoV-2 replication. This antiviral activity was blocked by pharmacologic inhibition of iNOS. IFN-γ also triggered a NO-mediated antiviral activity in SARS-CoV-2 infected human lung epithelial cell lines A549-ACE2 and Calu-3. IL-1β enhanced IFN-γ induction of NO, but it had little effect on antiviral activity. Discussion: Given that IFN-g has been shown to be produced by CD8+ T cells in the early response to SARS-CoV-2, our findings in human lung epithelial cell lines, of an IFN-γ-triggered, NO-dependent, links the adaptive immune response to an innate antiviral pathway in host defense against SARS-CoV-2. These results underscore the importance of IFN-γ and NO in the antiviral response and provide insights into potential therapeutic strategies for COVID-19. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2023 Silva, Krogstad, Teles, Andrade, Rajfer, Ferrini, Yang, Bloom and Modlin.) |
| References: | N Engl J Med. 2020 Feb 20;382(8):727-733. (PMID: 31978945) Cell Host Microbe. 2020 May 13;27(5):841-848.e3. (PMID: 32289263) J Neuroimmunol. 1998 Mar 1;82(2):133-9. (PMID: 9585809) J Virol. 2005 Feb;79(3):1966-9. (PMID: 15650225) Front Immunol. 2022 Aug 30;13:954391. (PMID: 36110850) Nat Commun. 2021 Mar 30;12(1):1967. (PMID: 33785743) Nat Immunol. 2001 Oct;2(10):907-16. (PMID: 11577346) Biochem J. 2017 Oct 10;474(20):3543-3557. (PMID: 28883123) Hypertension. 1995 Mar;25(3):421-30. (PMID: 7875768) Annu Rev Immunol. 1997;15:323-50. (PMID: 9143691) Front Immunol. 2022 Feb 14;13:844304. (PMID: 35237279) Br J Pharmacol. 2007 Jun;151(3):305-21. (PMID: 17401442) Int Immunopharmacol. 2021 Oct;99:107916. (PMID: 34224994) J Exp Med. 1997 Nov 3;186(9):1495-502. (PMID: 9348307) J Immunol. 2019 Aug 15;203(4):911-921. (PMID: 31235553) Nat Commun. 2020 Nov 18;11(1):5885. (PMID: 33208793) Eur J Immunol. 2006 Oct;36(10):2649-57. (PMID: 16955520) Nature. 2021 Mar;591(7849):293-299. (PMID: 33494095) J Interferon Cytokine Res. 2015 Jul;35(7):540-53. (PMID: 25830339) Nat Immunol. 2021 Jan;22(1):74-85. (PMID: 32999467) J Genet Eng Biotechnol. 2021 Oct 22;19(1):165. (PMID: 34677688) Cell. 2020 Nov 12;183(4):996-1012.e19. (PMID: 33010815) Cell Rep. 2022 Feb 15;38(7):110387. (PMID: 35134331) Immunity. 2022 Mar 8;55(3):423-441.e9. (PMID: 35139355) J Leukoc Biol. 2015 Jun;97(6):1111-9. (PMID: 25801769) Nature. 2021 Sep;597(7875):268-273. (PMID: 34320609) Int J Mol Sci. 2021 Mar 01;22(5):. (PMID: 33804447) PLoS One. 2017 May 11;12(5):e0177269. (PMID: 28493939) Immunity. 2021 May 11;54(5):1066-1082.e5. (PMID: 33951417) Nitric Oxide. 2020 Oct 1;103:4-8. (PMID: 32681986) Eur J Pharmacol. 1995 Dec 29;294(2-3):703-12. (PMID: 8750736) Hepatology. 1996 Apr;23(4):797-802. (PMID: 8666334) Cell. 2021 Apr 1;184(7):1895-1913.e19. (PMID: 33657410) Sci Immunol. 2018 Aug 31;3(26):. (PMID: 30171080) Sci Transl Med. 2011 Oct 12;3(104):104ra102. (PMID: 21998409) Cancer Res. 2019 Oct 1;79(19):5034-5047. (PMID: 31409640) Cells. 2021 Aug 27;10(9):. (PMID: 34571865) Mol Cell. 2018 Sep 6;71(5):825-840.e6. (PMID: 30100266) Cell Death Discov. 2020 Dec 8;6(1):141. (PMID: 33293514) Nat Immunol. 2021 Jan;22(1):32-40. (PMID: 33277638) Cytokine. 2018 Dec;112:27-31. (PMID: 30145061) Nat Methods. 2012 Jun 28;9(7):676-82. (PMID: 22743772) PLoS Pathog. 2017 Jan 5;13(1):e1006103. (PMID: 28056107) Science. 2021 Oct 22;374(6566):eabj9853. (PMID: 34519540) Nat Med. 2021 Jan;27(1):78-85. (PMID: 33184509) J Med Virol. 2021 Oct;93(10):5710-5711. (PMID: 34196421) J Biol Chem. 2020 Oct 9;295(41):13958-13964. (PMID: 32587093) Biochemistry. 1993 Aug 24;32(33):8512-7. (PMID: 7689333) Int J Cell Biol. 2010;2010:214074. (PMID: 20182529) Science. 2020 Aug 7;369(6504):706-712. (PMID: 32527925) Biochem Biophys Res Commun. 1998 Jul 30;248(3):871-8. (PMID: 9704020) Proc Natl Acad Sci U S A. 1988 Jul;85(14):5259-63. (PMID: 3134658) Med. 2021 Oct 8;2(10):1111-1113. (PMID: 34661183) Immunity. 1998 Jan;8(1):77-87. (PMID: 9462513) Emerg Infect Dis. 2020 Jun;26(6):1266-1273. (PMID: 32160149) Cell Rep. 2020 Oct 6;33(1):108234. (PMID: 32979938) J Immunol. 2015 Sep 1;195(5):1911-20. (PMID: 26297790) PLoS Pathog. 2018 Nov 28;14(11):e1007420. (PMID: 30485383) Biochim Biophys Acta. 1999 May 5;1411(2-3):401-14. (PMID: 10320672) Sci Immunol. 2021 May 25;6(59):. (PMID: 34035118) PLoS One. 2016 Oct 28;11(10):e0164438. (PMID: 27792742) mBio. 2020 Sep 10;11(5):. (PMID: 32913009) Cell Mol Immunol. 2020 May;17(5):533-535. (PMID: 32203188) Nat Rev Immunol. 2012 Apr 25;12(5):367-82. (PMID: 22531325) Nat Commun. 2020 Aug 6;11(1):3910. (PMID: 32764693) Cell. 2020 Aug 6;182(3):734-743.e5. (PMID: 32643603) Crit Care Res Pract. 2010;2010:. (PMID: 20948883) Crit Care. 2020 Nov 12;24(1):645. (PMID: 33183348) Front Immunol. 2020 May 01;11:827. (PMID: 32425950) Front Immunol. 2022 Sep 26;13:953502. (PMID: 36225915) Kidney Int. 2002 Feb;61(2):444-55. (PMID: 11849384) Front Immunol. 2020 Sep 29;11:585647. (PMID: 33133104) Med. 2021 Oct 08;2(10):1163-1170.e2. (PMID: 34568856) J Virol Methods. 2011 Jun;174(1-2):144-9. (PMID: 21458491) Nature. 2020 Aug;584(7821):463-469. (PMID: 32717743) N Engl J Med. 2023 Feb 9;388(6):518-528. (PMID: 36780676) Anal Chem. 1998 Jul 1;70(13):2446-53. (PMID: 9666719) Science. 1993 Sep 10;261(5127):1445-8. (PMID: 7690156) Cell. 2020 May 28;181(5):1036-1045.e9. (PMID: 32416070) Cell Host Microbe. 2021 Jul 14;29(7):1052-1062. (PMID: 34022154) Redox Biol. 2020 Oct;37:101734. (PMID: 33007504) World J Virol. 2016 May 12;5(2):85-6. (PMID: 27175354) Crit Care Med. 2011 Sep;39(9):2087-98. (PMID: 21552122) Viruses. 2022 Jun 23;14(7):. (PMID: 35891350) Nat Immunol. 2003 Jan;4(1):69-77. (PMID: 12483210) Science. 2022 Feb 25;375(6583):864-868. (PMID: 35076256) Cell. 2021 Jan 7;184(1):149-168.e17. (PMID: 33278357) Science. 2001 Feb 23;291(5508):1544-7. (PMID: 11222859) J Virol. 2007 Aug;81(16):8685-91. (PMID: 17522204) PLoS Pathog. 2020 Oct 1;16(10):e1008461. (PMID: 33002089) Science. 2020 Aug 7;369(6504):718-724. (PMID: 32661059) Am J Respir Cell Mol Biol. 1998 Aug;19(2):308-15. (PMID: 9698604) Dev Biol. 2007 Sep 15;309(2):193-207. (PMID: 17698055) Nat Immunol. 2020 Sep;21(9):1107-1118. (PMID: 32788748) |
| معلومات مُعتمدة: | R01 AI166313 United States AI NIAID NIH HHS; R01 AR040312 United States AR NIAMS NIH HHS; P50 AR080594 United States AR NIAMS NIH HHS; R01 AI022553 United States AI NIAID NIH HHS; R01 AR074302 United States AR NIAMS NIH HHS; R01 AR073252 United States AR NIAMS NIH HHS; P30 AI028697 United States AI NIAID NIH HHS |
| فهرسة مساهمة: | Keywords: CD8 lymphocytes; COVID-19; SARS-CoV-2; T cell response; interferon; nitric oxide; viral immunity |
| المشرفين على المادة: | EC 3.4.17.23 (Angiotensin-Converting Enzyme 2) 82115-62-6 (Interferon-gamma) 31C4KY9ESH (Nitric Oxide) |
| تواريخ الأحداث: | Date Created: 20240101 Date Completed: 20240103 Latest Revision: 20240327 |
| رمز التحديث: | 20240329 |
| مُعرف محوري في PubMed: | PMC10755032 |
| DOI: | 10.3389/fimmu.2023.1284148 |
| PMID: | 38162653 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2023.1284148 |